> This is like comparing big pharma with generic manufacturers who can skip the R&D. While these drugs are not 1 to 1 copies, we are still comparing apples to apples, but with a 90% price cut.

Weird! It's almost like distillation is bad for the long-term growth of the industry, just like generic manufacturers would be if they could release the generic versions of drugs 2 weeks after the original R&D completes.

Very strange sentence to include in an article after saying "I don't care at all about distillation" up at the top. Can the author not hear themselves?